These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 37098169)

  • 1. Can Baseline [
    Bianchi A; De Rimini ML; Sciuto R; Annovazzi A; Di Traglia S; Bauckneht M; Lanfranchi F; Morbelli S; Nappi AG; Ferrari C; Rubini G; Panareo S; Urso L; Bartolomei M; D'Arienzo D; Valente T; Rossetti V; Caroli P; Matteucci F; Aricò D; Bombaci M; Caponnetto D; Bertagna F; Albano D; Dondi F; Gusella S; Spimpolo A; Carriere C; Balma M; Buschiazzo A; Gallicchio R; Storto G; Ruffini L; Scarlattei M; Baldari G; Cervino AR; Cuppari L; Burei M; Trifirò G; Brugola E; Zanini CA; Alessi A; Fuoco V; Seregni E; Deandreis D; Liberini V; Moreci AM; Ialuna S; Pulizzi S; Evangelista L
    Cancer Biother Radiopharm; 2023 May; 38(4):256-267. PubMed ID: 37098169
    [No Abstract]   [Full Text] [Related]  

  • 2. Cancer immunotherapy is accompanied by distinct metabolic patterns in primary and secondary lymphoid organs observed by non-invasive
    Schwenck J; Schörg B; Fiz F; Sonanini D; Forschner A; Eigentler T; Weide B; Martella M; Gonzalez-Menendez I; Campi C; Sambuceti G; Seith F; Quintanilla-Martinez L; Garbe C; Pfannenberg C; Röcken M; la Fougere C; Pichler BJ; Kneilling M
    Theranostics; 2020; 10(2):925-937. PubMed ID: 31903160
    [No Abstract]   [Full Text] [Related]  

  • 3. Prognostic value of 2-[
    Schweighofer-Zwink G; Manafi-Farid R; Kölblinger P; Hehenwarter L; Harsini S; Pirich C; Beheshti M
    Eur J Radiol; 2022 Jan; 146():110107. PubMed ID: 34922117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Ito K; Teng R; Schöder H; Humm JL; Ni A; Michaud L; Nakajima R; Yamashita R; Wolchok JD; Weber WA
    J Nucl Med; 2019 Mar; 60(3):335-341. PubMed ID: 30413661
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 18F-FDG PET/CT for the prediction and detection of local recurrence after radiofrequency ablation of malignant lung lesions.
    Singnurkar A; Solomon SB; Gönen M; Larson SM; Schöder H
    J Nucl Med; 2010 Dec; 51(12):1833-40. PubMed ID: 21078787
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Value of
    Vekens K; Everaert H; Neyns B; Ilsen B; Decoster L
    Clin Lung Cancer; 2021 Sep; 22(5):432-440. PubMed ID: 33879398
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Using positron emission tomography (PET) response criteria in solid tumours (PERCIST) 1.0 for evaluation of 2'-deoxy-2'-[18F] fluoro-D-glucose-PET/CT scans to predict survival early during treatment of locally advanced non-small cell lung cancer (NSCLC).
    Fledelius J; Khalil AA; Hjorthaug K; Frøkiaer J
    J Med Imaging Radiat Oncol; 2016 Apr; 60(2):231-8. PubMed ID: 26678718
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and Prognostic Value of
    Albano D; Familiari D; Fornito MC; Scalisi S; Laudicella R; Galia M; Grassedonio E; Ruggeri A; Ganduscio G; Messina M; Spada M; Midiri M; Alongi P
    Curr Radiopharm; 2020; 13(1):42-47. PubMed ID: 31595860
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progression free survival related to
    Zhu X; Wu S; Yuan X; Wang H; Ma C
    Hell J Nucl Med; 2019; 22(2):123-130. PubMed ID: 31273354
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Absolute number of new lesions on
    Anwar H; Sachpekidis C; Winkler J; Kopp-Schneider A; Haberkorn U; Hassel JC; Dimitrakopoulou-Strauss A
    Eur J Nucl Med Mol Imaging; 2018 Mar; 45(3):376-383. PubMed ID: 29124281
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The value of
    Ayati N; Sadeghi R; Kiamanesh Z; Lee ST; Zakavi SR; Scott AM
    Eur J Nucl Med Mol Imaging; 2021 Feb; 48(2):428-448. PubMed ID: 32728798
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The predictive value of
    Mattoli MV; Massaccesi M; Castelluccia A; Scolozzi V; Mantini G; Calcagni ML
    Radiat Oncol; 2017 Jan; 12(1):4. PubMed ID: 28057034
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The prognostic value of [
    Sachpekidis C; Weru V; Kopp-Schneider A; Hassel JC; Dimitrakopoulou-Strauss A
    Eur J Nucl Med Mol Imaging; 2023 Jul; 50(9):2699-2714. PubMed ID: 37099131
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic and diagnostic value of [18F]FDG-PET/CT in restaging patients with small cell lung carcinoma: an Italian multicenter study.
    Quartuccio N; Evangelista L; Alongi P; Caobelli F; Altini C; Cistaro A; Lambertini A; Schiorlin I; Popescu CE; Linguanti F; Laudicella R; Scalorbi F; Di Pierro G; Asabella AN; Cuppari L; Margotti S; Lima GM; Scalisi S; Pacella S; Kokomani A; Ciaccio A; Sturiale L; Vento A; Cardile D; Baldari S; Panareo S; Fanti S; Rubini G; Schillaci O; Chiaravalloti A;
    Nucl Med Commun; 2019 Aug; 40(8):808-814. PubMed ID: 31136534
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Can benign lymphoid tissue changes in
    Sachpekidis C; Larribère L; Kopp-Schneider A; Hassel JC; Dimitrakopoulou-Strauss A
    Cancer Immunol Immunother; 2019 Feb; 68(2):297-303. PubMed ID: 30478475
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value of volumetric PET parameters at early response evaluation in melanoma patients treated with immunotherapy.
    Nakamoto R; Zaba LC; Rosenberg J; Reddy SA; Nobashi TW; Davidzon G; Aparici CM; Nguyen J; Moradi F; Iagaru A; Franc BL
    Eur J Nucl Med Mol Imaging; 2020 Nov; 47(12):2787-2795. PubMed ID: 32296882
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessing immune organs on
    Prigent K; Lasnon C; Ezine E; Janson M; Coudrais N; Joly E; Césaire L; Stefan A; Depontville M; Aide N
    Eur J Nucl Med Mol Imaging; 2021 Jul; 48(8):2573-2585. PubMed ID: 33432374
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer.
    Liao S; Penney BC; Wroblewski K; Zhang H; Simon CA; Kampalath R; Shih MC; Shimada N; Chen S; Salgia R; Appelbaum DE; Suzuki K; Chen CT; Pu Y
    Eur J Nucl Med Mol Imaging; 2012 Jan; 39(1):27-38. PubMed ID: 21946983
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 18F-FDG PET/CT in non-small-cell lung cancer patients: a potential predictive biomarker of response to immunotherapy.
    Evangelista L; Cuppari L; Menis J; Bonanno L; Reccia P; Frega S; Pasello G
    Nucl Med Commun; 2019 Aug; 40(8):802-807. PubMed ID: 31045745
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.